|100/50mcg 1inhaler||$134.99||$134.99 per inhaler|
|100/50mcg 2inhalers||$225.99||$113.00 per inhaler|
|100/50mcg 3inhalers||$326.99||$109.00 per inhaler|
|250/50mcg 1inhaler||$152.99||$152.99 per inhaler|
|250/50mcg 2inhalers||$270.99||$135.50 per inhaler|
|250/50mcg 3inhalers||$351.99||$117.33 per inhaler|
|500/50mcg 1inhaler||$170.99||$170.99 per inhaler|
|500/50mcg 2inhalers||$315.99||$158.00 per inhaler|
|500/50mcg 3inhalers||$432.99||$144.33 per inhaler|
Advair Discus is a bestselling antiasthmatic agent in the US market and the latest achievement in science. This is a combination of two powder substances for inhalation – fluticasone and salmeterol. The medication has the following indications for use:
- basic therapy in diseases accompanied by reversible airway obstruction (including bronchial asthma in children and adults);
- supportive therapy in COPD.
In rare cases, Advair may cause:
- paradoxical bronchospasm.
- cardiac arrhythmias (including atrial fibrillation, supraventricular tachycardia, extrasystole).
- abdominal pains;
- taste disorders;
- oropharynx mucous membranes irritation.
- local edema.
- painful muscle spasms;
- oral moniliasis.
- hypersensitivity skin reactions;
- anaphylactic reactions;
- adrenal function suppression;
- stunted growth;
- Cushing syndrome;
- cushingoid appearance;
- bone mineral density reduction;
- sleep disorders;
- behavioral changes, including hyperactivity and irritability.
Do not use Advair in the presence of any of the following conditions:
- children under 4 years;
- hypersensitivity to drug components.
- pulmonary tuberculosis;
- fungal, viral or bacterial respiratory infections;
- uncontrolled hypokalemia;
- idiopathic hypertrophic subaortic stenosis;
- uncontrolled hypertension;
- QT interval elongation on ECG;
- ischemic heart disease;
- hypoxia of different origin;
- lactation period.
- The drug is intended for long-term treatment and exacerbations prevention, rather than rapid relief of symptoms (in this case, short-action inhaled bronchodilators should be used);
- The drug should be taken regularly, even if there are no symptoms;
- The increased need for short-acting bronchodilator indicates worsening of the disease;
- Do not withdraw drug abruptly;
- Long-term use of any inhaled glucocorticosteroids, especially in high dosage, may cause systemic effects. It is important that the therapeutic effect of inhaled glucocorticosteroids dose is reduced to a minimal dose which is effective;
- It is recommended to regularly monitor growth dynamics in children receiving inhaled glucocorticosteroids for a long time;
- If the drug should be withdrawn because of salmeterol overdose, the patient should be prescribed appropriate replacement glucocorticosteroids therapy;
- In rare cases, when switching to Advair from systemic glucocorticosteroids, hypereosinophilia may occur (including Churg-Strauss syndrome). This usually occurs during systemic glucocorticosteroids dose reduction or withdrawal, but causal relationships have not been established;
- When switching from systemic glucocorticosteroids, allergic reactions may also occur (including allergic rhinitis, eczema), which previously were suppressed by systemic drugs.
Be careful when using Advair with any of the following drugs:
- non-selective and cardioselective beta-adrenergic blocking agents;
- inhaled fluticasone propionate;
- CYP3A4 inhibitors and fluticasone propionate;
- Ritonavir (highly active CYP3A4 isozyme inhibitor);
- xanthine derivatives, glucocorticosteroids and diuretics;
- monoamine oxidase inhibitors;
- tricyclic antidepressants;
- cromoglicic acid.